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Background: The Gleason grading system is a powerful predictor of prostate cancer (PCa) prognosis.
Gleason scores (GS) of 8e10 are considered as a single high-risk grade category, and Gleason Pattern 5
(GP5) predicts biochemical recurrence. We report the clinical outcomes of patients treated with 125I
prostate brachytherapy for clinically localized PCa and prognosis in the presence or absence of GP5.
Methods: We enrolled 316 patients with T1ceT2N0M0 PCa and undergoing prostate brachytherapy
treatment. All patients were followed up for  1 year. The primary endpoint was biochemical recurrence-
free survival. Biochemical recurrence was deﬁned by the Phoenix criteria. Survival curves were calculated
by the KaplaneMeier method, and the prognostic impact of biochemical recurrence was analyzed using a
Cox proportional hazards model.
Results: The 5-year biochemical recurrence-free survival rate for all patients was 95.2%, and according to
the D’Amico risk classiﬁcation criteria, the rates were 98.7% for patients in low-risk, 96.9% in
intermediate-risk, and 81.1% in high-risk groups (P < 0.0001). The 5-year biochemical recurrence-free
survival rates for patients with GS8 or GS9e10 were 87.7% and 61.5%, respectively (P ¼ 0.0057). Multi-
variate analysis found that GS and clinical T stage were independent predictors of biochemical
recurrence.
Conclusions: The presence of GP5 in GS9e10 prostate cancer has a worse prognosis than GS8 prostate
cancer in the absence of GP5 for patients undergoing prostate brachytherapy.
Copyright © 2016 Asian Paciﬁc Prostate Society, Published by Elsevier. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Iodine-125 prostate brachytherapy (PB) is an established mo-
dality for treating localized prostate cancer (PCa), with favorable
outcomes similar to those obtained by radical prostatectomy and
external beam radiation therapy (EBRT).1,2 The number of PCa pa-
tients with PB has been increasing rapidly in Japan.3 Gleason
grading is an important predictor of PCa outcome,4 and Gleason
scores (GS) of 8e10 represent a high-risk grade group. The presence
of Gleason Pattern 5 (GP5) predicts for biochemical recurrence,5,6
but there are few reports on the impact of GP5 on clinical out-
comes of patients with brachytherapy. In this report, we summarize
7 years of clinical experience and outcomes of patients with PB at
our institution, and evaluate the prognostic value of GP5 with re-
gard to biochemical recurrence.Kanazawa Medical Center,
50, Japan.
ino).
ciﬁc Prostate Society, Published b2. Materials and methods
We enrolled 316 patients with T1ceT2N0M0 PCa and treated
with PB at the Kanazawa Medical Center (Kanazawa, Japan) be-
tween 2007 and 2014. We followed the patients for  1 year. Pa-
tients were stratiﬁed into prognostic groups by D’Amico risk
classiﬁcation criteria.7 Low-risk patients had prostate-speciﬁc an-
tigen (PSA)  10 ng/mL, GS  6, and clinical stage  T2a tumors.
Intermediate-risk patients had PSA > 10 ng/mL and  20 ng/mL,
and/or GS ¼ 7, and/or clinical stage T2b tumors. High-risk patients
had PSA > 20 ng/mL and/or GS  8 and/or clinical stage  T2c tu-
mors. Most low-risk patients received PB without supplemental
EBRT. High-risk patients received PB with EBRT, and intermediate-
risk patients were given supplemental EBRT as determined by their
physician depending on the PSA value and biopsy-positive core
rate, i.e., the percentage of cores containing tumor. A total of 123
patients (30.1%) received neoadjuvant androgen deprivation ther-
apy (ADT) for prostate volume reduction, to be worried the pro-
gression of disease until PB, or if it had already been started byy Elsevier. This is an open access article under the CC BY-NC-ND license (http://
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PB with EBRT was administered at a dose of 110 Gy with an addi-
tional 45 Gy of supplemental EBRT. Planned follow-up was by PSA
blood tests every 3 months for the ﬁrst 2 years, and every 3e6
months thereafter. The primary outcome was biochemical
recurrence-free survival (bRFS). Biochemical recurrence was
determined by the Phoenix criteria.8 If biochemical recurrence was
conﬁrmed and it persisted, as shown by PSA increase, the patient
was further evaluated by prostate biopsy, computed tomography,
and bone scan so that recurrence could be assured and character-
ized by a physician. PSA bounce was deﬁned as an increase of
 0.4 ng/mL above an initial PSA nadir and a subsequent decline to
or below that initial nadir without treatment, and patients meeting
the bounce phenomenon were excluded from the analysis of
recurrence. Survival curves were calculated by the KaplaneMeier
method, and differences in time-adjusted rates were evaluated for
signiﬁcance by log-rank test. The prognostic impact of biochemical
recurrence was analyzed in a Cox proportional hazards model. All
tests were two sided, and the statistical signiﬁcance was set at
P < 0.05.3. Results
Patient characteristics are shown in Table 1. The median patient
age was 69 years (range, 51e84 years) and the median follow-up
duration was 48.2 months (range, 12e103 months). Of the 316
patients included in this study, 237 (75.0%) were in clinical
stage T1c, 58 (18.4%) in T2a, 18 (5.7%) in T2b, and three (0.9%) in
T2c. The median PSA level at diagnosis was 5.6 ng/mL (range,
0.67e84.44 ng/mL) and the GSwere 6 (128, 40.5%), 7 (141, 44.6%),
and  8 (47, 14.9%). According to the D’Amico risk criteria, 114 pa-
tients (36.1%) were at low risk, 144 (45.5%) at intermediate risk, and
58 (18.4%) at high risk. Of all patients, 221 (69.9%) were treatedwith
PB without EBRT. A total of 123 patients (38.9%) were given neo-
adjuvant ADT for a median duration of 5 months. Only 10 patients
(3.2%) received adjuvant ADT (data not shown). Additional patient
characteristics, including GS, age, PSA, clinical T stage, combined
EBRT therapy, and use of ADT are summarized in Table 2. Among
high-risk patients, 34 (10.8%) had GS8 and all of them had no GP5.Table 1
Patient characteristics.
Median age, y (range) 69 (51e84) n ¼ 316
Follow-up, mo (range) Median 48.2 (12e103)
Clinical stage, n (%) T1c 237 (75.0)
T2a 58 (18.4)
T2b 18 (5.7)
T2c 3 (0.9)
Gleason score, n (%)  6 128 (40.5)
7 141 (44.6)
 8 47 (14.9)
PSA at diagnosis, ng/mL (range) Median 5.6 (0.67e84.44)
 10 258 (81.7)
10e20 39 (12.3)
 20 19 (6.0)
Positive core rate, % (range) Median 20.0 (7.1e100)
Prostate volume, mL (range) Median 20.9 (7.0e46.5)
Neoadjuvant hormone therapy, n (%) þ 123 (38.9)
e 193 (61.1)
Combined external beam
radiotherapy, n (%)
þ 95 (30.1)
e 221 (69.9)
D'Amico risk classiﬁcation, n (%)a) Low 114 (36.1)
Intermediate 144 (45.5)
High 58 (18.4)
a) Low risk: PSA  10 and Gleason score  6 and stage  T2a; intermediate risk:
PSA > 10 and  20 and/or Gleason score ¼6 and/or stage T2b; high risk: PSA > 20
and/or Gleason score  8 and/or stage  T2c, PSA, prostate-speciﬁc antigen.Thirteen patients (4.1%) had GS9e10. As expected, patients with
higher GS tended to have higher PSA values and a more advanced T
stage.
Fig. 1 shows the survival curves calculated by the KaplaneMeier
method. The 5-year and 8-year overall survival rates were 95.7%
and 91.6%, respectively, and the corresponding bRFS rates were
95.2% and 83.3%, respectively (Fig. 1A). The 5-year bRFS rates for
low-, intermediate-, and high-risk patients (Fig. 1B) were 98.7%,
96.9%, and 81.1%, respectively (P < 0.0001). The 5-year bRFS rates
for patients with GS  6, 7, or  8 were 98.9%, 95.8%, and 80.4%,
respectively (P < 0.0001; Fig. 1C). Remarkably, the 5-year bRFS rates
for patients with GS8 (87.7%) and GS9e10 (61.5%) were signiﬁcantly
different (P ¼ 0.0057; Fig. 1D). Recurrence occurred in 16 patients
(5.1%), and nine patients died during follow-up but only one patient
died of PCa.
Table 3 shows the characteristics of patients who experienced
recurrence. Ten of the 58 patients (17.2%) were in the high-risk
group at inclusion, and six of the 258 (2.3%) were low- or
intermediate-risk patients. One was a low-risk patient and ﬁve
were intermediate-risk patients. Two recurrence sites were local
(12.5%), three were lymph nodes (18.8%), and three were bone
(18.8%). One recurrence was both local and in bone (6.2%), one was
in both lymph nodes and bone (6.2%), and six were at an unknown
site or sites (37.5%). Four of six patients with GS9e10 tumors
experienced metastases.
Multivariate Cox regression analysis including age, GS, PSA,
clinical T stage, and biopsy-positive core rate (Table 4) found that
GS (hazard ratio ¼ 3.43) and clinical T stage (hazard ratio ¼ 4.59)
were independent predictors of biochemical recurrence.
4. Discussion
Since 2003, when PB was ﬁrst authorized, many cancer in-
stitutes throughout Japan have registered to administer PB therapy.
The reported 5-year bRFS rates for patients in the low-, interme-
diate-, and high-risk groups are  90%, 80e90%, and 70e80%,
respectively.9e11 The corresponding bRFS rates at our treatment
center were 98.7%, 96.9%, and 81.1%, respectively, which are similar
to those of the previous reports.
Our high-risk patients had a poor prognosis, and those with
GS9e10 PCa had a signiﬁcantly worse bRFS rate than those with
GS8 disease, who also had a relatively poor prognosis. In other
words, the presence of GP5 predicted the worse clinical outcome.
Sabolch et al5 reported that the presence of GP5 predicted lower
cause-speciﬁc survival and overall survival in PCa patients treated
with EBRT compared with GS8 patients in cases without GP5. In
that series, the presence of GP5 predicted worse clinical outcome
and a short interval from biochemical failure to metastasis.5 In our
series, six of 13 patients with GP5 experienced biochemical recur-
rence and four experienced advancedmetastasis. This suggests that
GP5 may have characteristics that predispose to metastasis.
Although the biological cause underlying worse outcomes in pa-
tients with GP5 is unknown, there are multiple alternative path-
ways that can drive a PCa toward the aggressiveness seen in the
presence of GP5.5 Horwitz et al12 reported long-term results of
Radiation Therapy Oncology Group Protocol 92-02 that demon-
strate a survival advantage for 24 months of ADT plus radiation
therapy in the treatment of locally advanced tumors with GS of
8e10. That result implies that the Protocol 92-02 regimen should
be the standard of treatment for these high-risk patients. By
contrast, androgen suppression probably contributes to the elimi-
nation of occult systemic disease while also potentiating external
irradiation by an additive, or supra-additive, effect on local control
through induction of apoptosis.13,14 Hence, long-term ADT plus
radiation therapy is considered more effective in high-risk cases
Fig. 1. Survival curves calculated by the KaplaneMeier method. (A) Survival rates for all patients (n ¼ 316). (B) Biochemical recurrence-free survival rates for all patients stratiﬁed by
the risk group. (C) Biochemical recurrence-free survival rates for all patients stratiﬁed by the Gleason score. (D) Biochemical recurrence-free survival rate for high-risk patients with
a Gleason score of 8 or 9e10, GS, Gleason scores; OS, overall survival; RFS, recurrence-free survival.
Table 2
Clinical features stratiﬁed by Gleason score.
Gleason score
 6 7 8 9, 10
n 128 (40%) 141 (45%) 34 (11%) 13 (4%)
Median age (range) 68 (51e84) 69 (54e84) 75 (54e83) 71 (56e77)
Median PSA (range) 4.98 (0.67e37.62) 5.69 (2.00e33.96) 7.90 (1.86e84.44) 10.08 (4.13e62.23)
Clinical stage
T1c-T2a 100% 92% 88% 62%
T2b 0% 6% 12% 38%
T2c 0% 2% 0% 0%
D'Amico risk classiﬁcation
Low 89% 0% 0% 0%
Intermediate 8% 95% 0% 0%
High 3% 5% 100% 100%
Combined EBRT 5% 33% 85% 100%
ADT use 33% 43% 44% 46%
ADT, androgen deprivation therapy; EBRT, external beam radiotherapy; PSA, prostate speciﬁc antigen.
Table 3
Characteristics of recurrence patients (n ¼ 16).
Risk group (No.of recurrence Pts) Median age T stage Gleason score PSA Recurrence site
Low
1(/114; 0.9%) intermediate
5(/144; 3.5%)
High
10(/58; 17.2%)
72 T1c: 5
T2a: 6
T2b: 4
T2c: 1
 6:2
7:5
8:3
9e10:6
 10:7
> 10,  20:5
> 20:4
Local: 2
LNs: 3
bone: 3
Local þ bone: 1
LNs þ bone: 1
Unknown: 6
LN, lymph node; PSA, prostate-speciﬁc antigen; Pts, patients.
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Table 4
Multivariate Cox regression analysis for biochemical recurrence.
P value Hazard rate 95.0% CI
Lower Upper
Age  70 0.196 2.321 0.647 8.328
GS  8 0.038 3.429 1.074 10.951
PSA  20 0.283 2.312 0.500 10.686
T stage T2 0.022 4.587 1.247 16.868
PCR  50% 0.932 0.940 0.227 3.888
CI, conﬁdence interval; GS, Gleason scores; PCR, positive core rate; PSA, prostate-
speciﬁc antigen.
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present when primary therapy starts.
Gleason scoring is a well-established system for describing
pathological stage and predicting oncological outcomes of men
with PCa. Pierorazio et al15 have recommended Gleason grades, and
prognostic grade groups, including GS 6 (prognostic Grade Group
1); GS 3 þ 4 ¼ 7 (prognostic Grade Group 2); GS 4 þ 3 ¼ 7 (prog-
nostic Grade Group 3); GS 4 þ 4 ¼ 8 (prognostic Grade Group 4);
and GS9e10 (prognostic Grade Group 5). In that series, the 5-year
bRFS rates were 96.6% in Grade Group 1, 88.1% in Group 2, 69.7%
in Group 3, 63.7% in Group 4, and 34.5% in Group 5 (P < 0.001) after
radical prostatectomy. Therefore, they suggested that men with
GS9e10 tumors will more accurately be considered to have more
aggressive tumors than those with GS8.15 In our study, the 5-year
bRFS rates were 98.9% in Grade Group 1, 96.2% in Group 2, 95.3%
in Group 3, 87.7% in Group 4, and 61.5% in Group 5 (P < 0.0001;
Fig. 2). As above, GS were independent predictors of biochemical
recurrence. The 5-year bRFS rates for patients with GS8 (i.e., Grade
Group 4) or GS9e10 (i.e., Grade Group 5) were signiﬁcantly
different. Thus, we can mention that Grade Group 5, based on the
presence of GP5, is an independent predictor of biochemical
recurrence. As the biochemical prognosis is signiﬁcantly worse in
GS9e10 than in GS8 groups, combinedmodality therapy such as PB,
EBRT, and long-term ADT should be considered for high-risk PCa
patients with GP5 disease. A Phase III, multicenter, randomized
controlled trial of trimodal therapy with 125I brachytherapy, EBRT,
and short- or long-term hormone therapy for high-risk PCa is
ongoing.16 We expect that the results of the short- or long-term
hormone therapy for high-risk PCa study will support trimodal
therapy for patients in Grade Group 5 and GP5.
This study had some limitations. First, this was a retrospective
study with duration of about 7 years. Second, the follow-up period
was relatively short; therefore, only biochemical recurrence wasFig. 2. Biochemical recurrence-free survival rates for all patients stratiﬁed by Gleason
grades.examined. Only one patient died from PCa during the observation
period in this study. Future studies are thus required to examine
cancer-speciﬁc survival rather than biochemical recurrence.
5. Conclusions
Although we achieved good outcomes with PB in low- and
intermediate-risk patients with PCa, prognosis in the high-risk
group was signiﬁcantly worse. The prognosis of patients with
GS9e10 based on the presence of GP5 (i.e., Grade Group 5) was
worse than that for GS8 tumors (i.e., Grade Group 4), and Gleason
grades may be useful for reﬂecting prognosis. Therefore, we should
reconsider the strategy for treating patients with GP5 tumors.
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